

Metachromatic Leukodystrophy Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/M27FA52BE0A5EN.html>

Date: August 2022

Pages: 107

Price: US\$ 3,250.00 (Single User License)

ID: M27FA52BE0A5EN

Abstracts

Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty. Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning. This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.

This report contains market size and forecasts of Metachromatic Leukodystrophy Treatment in Global, including the following market information:

Global Metachromatic Leukodystrophy Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Metachromatic Leukodystrophy Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Tablet Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Metachromatic Leukodystrophy Treatment include ArmaGen, Inc., GlaxoSmithKline Plc, Recursion Pharmaceuticals, Inc., RegenxBio, Inc., Takeda Pharmaceutical Company Limited, Orchard Therapeutics Plc, Magenta Therapeutics, Shire Plc and Oxyrane, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metachromatic Leukodystrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Metachromatic Leukodystrophy Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Metachromatic Leukodystrophy Treatment Market Segment Percentages, by Type, 2021 (%)

Tablet

Capsule

Others

Global Metachromatic Leukodystrophy Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Metachromatic Leukodystrophy Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Laboratory

Others

Global Metachromatic Leukodystrophy Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Metachromatic Leukodystrophy Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Metachromatic Leukodystrophy Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Metachromatic Leukodystrophy Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

ArmaGen, Inc.

GlaxoSmithKline Plc

Recursion Pharmaceuticals, Inc.

RegenxBio, Inc.

Takeda Pharmaceutical Company Limited

Orchard Therapeutics Plc

Magenta Therapeutics

Shire Plc

Oxyrane

NanoMedSyn

Juventas Therapeutics

GenSight Biologics

Inozyme Pharma

ONL Therapeutics

AngioChem

Cabaletta Bio

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Metachromatic Leukodystrophy Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Metachromatic Leukodystrophy Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL METACHROMATIC LEUKODYSTROPHY TREATMENT OVERALL MARKET SIZE

- 2.1 Global Metachromatic Leukodystrophy Treatment Market Size: 2021 VS 2028
- 2.2 Global Metachromatic Leukodystrophy Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Metachromatic Leukodystrophy Treatment Players in Global Market
- 3.2 Top Global Metachromatic Leukodystrophy Treatment Companies Ranked by Revenue
- 3.3 Global Metachromatic Leukodystrophy Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Metachromatic Leukodystrophy Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Metachromatic Leukodystrophy Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Metachromatic Leukodystrophy Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Metachromatic Leukodystrophy Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Metachromatic Leukodystrophy Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Metachromatic Leukodystrophy Treatment Market Size Markets, 2021 & 2028

4.1.2 Tablet

4.1.3 Capsule

4.1.4 Others

4.2 By Type - Global Metachromatic Leukodystrophy Treatment Revenue & Forecasts

4.2.1 By Type - Global Metachromatic Leukodystrophy Treatment Revenue, 2017-2022

4.2.2 By Type - Global Metachromatic Leukodystrophy Treatment Revenue, 2023-2028

4.2.3 By Type - Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Metachromatic Leukodystrophy Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Laboratory

5.1.5 Others

5.2 By Application - Global Metachromatic Leukodystrophy Treatment Revenue & Forecasts

5.2.1 By Application - Global Metachromatic Leukodystrophy Treatment Revenue, 2017-2022

5.2.2 By Application - Global Metachromatic Leukodystrophy Treatment Revenue, 2023-2028

5.2.3 By Application - Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

- 6.1 By Region - Global Metachromatic Leukodystrophy Treatment Market Size, 2021 & 2028
- 6.2 By Region - Global Metachromatic Leukodystrophy Treatment Revenue & Forecasts
 - 6.2.1 By Region - Global Metachromatic Leukodystrophy Treatment Revenue, 2017-2022
 - 6.2.2 By Region - Global Metachromatic Leukodystrophy Treatment Revenue, 2023-2028
 - 6.2.3 By Region - Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028
- 6.3 North America
 - 6.3.1 By Country - North America Metachromatic Leukodystrophy Treatment Revenue, 2017-2028
 - 6.3.2 US Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.3.3 Canada Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.3.4 Mexico Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
- 6.4 Europe
 - 6.4.1 By Country - Europe Metachromatic Leukodystrophy Treatment Revenue, 2017-2028
 - 6.4.2 Germany Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.4.3 France Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.4.4 U.K. Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.4.5 Italy Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.4.6 Russia Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.4.7 Nordic Countries Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.4.8 Benelux Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
- 6.5 Asia
 - 6.5.1 By Region - Asia Metachromatic Leukodystrophy Treatment Revenue, 2017-2028
 - 6.5.2 China Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.5.3 Japan Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.5.4 South Korea Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.5.5 Southeast Asia Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.5.6 India Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
- 6.6 South America
 - 6.6.1 By Country - South America Metachromatic Leukodystrophy Treatment Revenue, 2017-2028
 - 6.6.2 Brazil Metachromatic Leukodystrophy Treatment Market Size, 2017-2028

- 6.6.3 Argentina Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
- 6.7 Middle East & Africa
 - 6.7.1 By Country - Middle East & Africa Metachromatic Leukodystrophy Treatment Revenue, 2017-2028
 - 6.7.2 Turkey Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.7.3 Israel Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.7.4 Saudi Arabia Metachromatic Leukodystrophy Treatment Market Size, 2017-2028
 - 6.7.5 UAE Metachromatic Leukodystrophy Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

- 7.1 ArmaGen, Inc.
 - 7.1.1 ArmaGen, Inc. Corporate Summary
 - 7.1.2 ArmaGen, Inc. Business Overview
 - 7.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Major Product Offerings
 - 7.1.4 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)
 - 7.1.5 ArmaGen, Inc. Key News
- 7.2 GlaxoSmithKline Plc
 - 7.2.1 GlaxoSmithKline Plc Corporate Summary
 - 7.2.2 GlaxoSmithKline Plc Business Overview
 - 7.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Major Product Offerings
 - 7.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)
 - 7.2.5 GlaxoSmithKline Plc Key News
- 7.3 Recursion Pharmaceuticals, Inc.
 - 7.3.1 Recursion Pharmaceuticals, Inc. Corporate Summary
 - 7.3.2 Recursion Pharmaceuticals, Inc. Business Overview
 - 7.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Major Product Offerings
 - 7.3.4 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)
 - 7.3.5 Recursion Pharmaceuticals, Inc. Key News
- 7.4 RegenxBio, Inc.
 - 7.4.1 RegenxBio, Inc. Corporate Summary
 - 7.4.2 RegenxBio, Inc. Business Overview
 - 7.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Major Product

Offerings

7.4.4 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.4.5 RegenxBio, Inc. Key News

7.5 Takeda Pharmaceutical Company Limited

7.5.1 Takeda Pharmaceutical Company Limited Corporate Summary

7.5.2 Takeda Pharmaceutical Company Limited Business Overview

7.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Major Product Offerings

7.5.4 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.5.5 Takeda Pharmaceutical Company Limited Key News

7.6 Orchard Therapeutics Plc

7.6.1 Orchard Therapeutics Plc Corporate Summary

7.6.2 Orchard Therapeutics Plc Business Overview

7.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Major Product Offerings

7.6.4 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.6.5 Orchard Therapeutics Plc Key News

7.7 Magenta Therapeutics

7.7.1 Magenta Therapeutics Corporate Summary

7.7.2 Magenta Therapeutics Business Overview

7.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Major Product Offerings

7.7.4 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.7.5 Magenta Therapeutics Key News

7.8 Shire Plc

7.8.1 Shire Plc Corporate Summary

7.8.2 Shire Plc Business Overview

7.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Major Product Offerings

7.8.4 Shire Plc Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.8.5 Shire Plc Key News

7.9 Oxyrane

7.9.1 Oxyrane Corporate Summary

7.9.2 Oxyrane Business Overview

7.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Major Product Offerings

7.9.4 Oxyrane Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.9.5 Oxyrane Key News

7.10 NanoMedSyn

7.10.1 NanoMedSyn Corporate Summary

7.10.2 NanoMedSyn Business Overview

7.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Major Product Offerings

7.10.4 NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.10.5 NanoMedSyn Key News

7.11 Juventas Therapeutics

7.11.1 Juventas Therapeutics Corporate Summary

7.11.2 Juventas Therapeutics Business Overview

7.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Major Product Offerings

7.11.4 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.11.5 Juventas Therapeutics Key News

7.12 GenSight Biologics

7.12.1 GenSight Biologics Corporate Summary

7.12.2 GenSight Biologics Business Overview

7.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Major Product Offerings

7.12.4 GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.12.5 GenSight Biologics Key News

7.13 Inozyme Pharma

7.13.1 Inozyme Pharma Corporate Summary

7.13.2 Inozyme Pharma Business Overview

7.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Major Product Offerings

7.13.4 Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.13.5 Inozyme Pharma Key News

7.14 ONL Therapeutics

7.14.1 ONL Therapeutics Corporate Summary

7.14.2 ONL Therapeutics Business Overview

7.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Major Product

Offerings

7.14.4 ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.14.5 ONL Therapeutics Key News

7.15 AngioChem

7.15.1 AngioChem Corporate Summary

7.15.2 AngioChem Business Overview

7.15.3 AngioChem Metachromatic Leukodystrophy Treatment Major Product Offerings

7.15.4 AngioChem Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.15.5 AngioChem Key News

7.16 Cabaletta Bio

7.16.1 Cabaletta Bio Corporate Summary

7.16.2 Cabaletta Bio Business Overview

7.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Major Product Offerings

7.16.4 Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue in Global Market (2017-2022)

7.16.5 Cabaletta Bio Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Metachromatic Leukodystrophy Treatment Market Opportunities & Trends in Global Market

Table 2. Metachromatic Leukodystrophy Treatment Market Drivers in Global Market

Table 3. Metachromatic Leukodystrophy Treatment Market Restraints in Global Market

Table 4. Key Players of Metachromatic Leukodystrophy Treatment in Global Market

Table 5. Top Metachromatic Leukodystrophy Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Metachromatic Leukodystrophy Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Metachromatic Leukodystrophy Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Metachromatic Leukodystrophy Treatment Product Type

Table 9. List of Global Tier 1 Metachromatic Leukodystrophy Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Metachromatic Leukodystrophy Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Metachromatic Leukodystrophy Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Metachromatic Leukodystrophy Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Metachromatic Leukodystrophy Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Metachromatic Leukodystrophy Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Metachromatic Leukodystrophy Treatment

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Metachromatic Leukodystrophy Treatment

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. ArmaGen, Inc. Corporate Summary

Table 31. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Product Offerings

Table 32. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. GlaxoSmithKline Plc Corporate Summary

Table 34. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Product Offerings

Table 35. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Recursion Pharmaceuticals, Inc. Corporate Summary

Table 37. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Product Offerings

Table 38. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. RegenxBio, Inc. Corporate Summary

Table 40. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Product Offerings

Table 41. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Takeda Pharmaceutical Company Limited Corporate Summary

Table 43. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy

Treatment Product Offerings

Table 44. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Orchard Therapeutics Plc Corporate Summary

Table 46. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Product Offerings

Table 47. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Magenta Therapeutics Corporate Summary

Table 49. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Product Offerings

Table 50. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Shire Plc Corporate Summary

Table 52. Shire Plc Metachromatic Leukodystrophy Treatment Product Offerings

Table 53. Shire Plc Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Oxyrane Corporate Summary

Table 55. Oxyrane Metachromatic Leukodystrophy Treatment Product Offerings

Table 56. Oxyrane Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. NanoMedSyn Corporate Summary

Table 58. NanoMedSyn Metachromatic Leukodystrophy Treatment Product Offerings

Table 59. NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Juventas Therapeutics Corporate Summary

Table 61. Juventas Therapeutics Metachromatic Leukodystrophy Treatment Product Offerings

Table 62. Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. GenSight Biologics Corporate Summary

Table 64. GenSight Biologics Metachromatic Leukodystrophy Treatment Product Offerings

Table 65. GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. Inozyme Pharma Corporate Summary

Table 67. Inozyme Pharma Metachromatic Leukodystrophy Treatment Product Offerings

Table 68. Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue (US\$,

Mn), (2017-2022)

Table 69. ONL Therapeutics Corporate Summary

Table 70. ONL Therapeutics Metachromatic Leukodystrophy Treatment Product Offerings

Table 71. ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 72. AngioChem Corporate Summary

Table 73. AngioChem Metachromatic Leukodystrophy Treatment Product Offerings

Table 74. AngioChem Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

Table 75. Cabaletta Bio Corporate Summary

Table 76. Cabaletta Bio Metachromatic Leukodystrophy Treatment Product Offerings

Table 77. Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Metachromatic Leukodystrophy Treatment Segment by Type in 2021
- Figure 2. Metachromatic Leukodystrophy Treatment Segment by Application in 2021
- Figure 3. Global Metachromatic Leukodystrophy Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Metachromatic Leukodystrophy Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Metachromatic Leukodystrophy Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Metachromatic Leukodystrophy Treatment Revenue in 2021
- Figure 8. By Type - Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028
- Figure 12. US Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028

Figure 24. China Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Metachromatic Leukodystrophy Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Metachromatic Leukodystrophy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Shire Plc Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Oxyrane Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. AngioChem Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Metachromatic Leukodystrophy Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/M27FA52BE0A5EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M27FA52BE0A5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

